Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis

Fig. 2

LEF1-AS1 interacts with miR-30-5p and regulates the miR-30-5p/PIK3R2 pathway. A MiR-30-5p was identified as a putative target of LEF1-AS1 by LncBase Predicted V.2 tools. B The luciferase activity of HFLS cells transfected with LEF1-ASI containing the wild- or mutant-type miR-30-5p binding sites and control miRNA or miR-30-5p. C RNA pull-down assay showing the direct interaction between LEF1-AS1 and miR-30-5p. D–E Relative expression of PIK3R2 mRNA and miR-30-5p in HFLS cells overexpressing LEF1-AS1. F–G Immunoblot showing relative expression of PIK3R2, PI3K, p-PI3K, AKT, and p-AKT proteins. Experiments were repeated thrice (**p < 0.01, ***p < 0.001, ****p < 0.0001)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us